

DATATRAK INTERNATIONAL, INC.
2025 ANNUAL RESULTS
May 1, 2026

Datatrak International, Inc. (“Datatrak”) (OTC: DTRK) is a SaaS, software-as-a-service, provider of enterprise resource planning (“ERP”) software across all industries. Datatrak Powered by Fountayn is focused on the healthcare and life sciences industries by providing software and data solutions for research studies, electronic medical records, and clinical trials for pharma, biotech, medical device, contract research organizations, sites, hospitals, governments, healthcare organizations, and academic institutions that are customizable and dynamic to fit the needs of various organizations. The company’s staff provides full-service solutions and support to ensure the success of our client’s objectives.

For the third consecutive year, the company grew revenues in 2025 and we look forward to continuing the trend in 2026. Revenue grew by 7.6% in 2025 compared to the prior year. Revenue for 2025 was \$7,191,180, compared to \$6,685,201 in 2024. Net operating income for 2025 was \$2,112,760, compared to \$2,000,210 in 2024.

The company achieved revenue growth in 2025 from 2024 in the face of industry and macroeconomic headwinds. The company also successfully deployed its ePRO, eCOA, eSource, and eConsent products which customers are reacting positively to.

2025 Highlights

- 7.6% revenue growth despite industry headwinds. This is our third consecutive year of revenue growth.
- Third consecutive year of profitability and continued profitability is projected for 2026.
- Successful new product releases in 2025 of ePRO, eCOA, eSource, and eConsent. Additional new product releases are planned for 2026.
- Successfully renewing multiple enterprise agreements with customers securing multimillion dollar recurring revenues for the company for the next several years and likely to expand.
- Expanding relationships with existing customers to add additional trials and as well as providing additional products and services.
- Successfully signing up new and returning customers who are dissatisfied with competitor’s products and services and prefer better pricing.

Datatrak will continue building upon the momentum established over the previous three years by continuing to grow revenues, attract new customers, and release new products with an ambitious product roadmap to continue innovating new solutions for healthcare and life sciences in order to accelerate clinical research.

Any forward-looking statements are based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in any forward looking statements, please see the Company’s report filed with the OTC Markets. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.